20,714 Shares in CVS Health Corporation $CVS Bought by Principle Wealth Partners LLC

Principle Wealth Partners LLC purchased a new stake in shares of CVS Health Corporation (NYSE:CVS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 20,714 shares of the pharmacy operator’s stock, valued at approximately $2,143,000.

A number of other large investors have also added to or reduced their stakes in CVS. Caitong International Asset Management Co. Ltd increased its position in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. purchased a new stake in shares of CVS Health during the fourth quarter worth about $26,000. Sankala Group LLC bought a new stake in shares of CVS Health in the fourth quarter worth about $28,000. Global Trust Asset Management LLC grew its stake in shares of CVS Health by 344.8% in the first quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares during the last quarter. Finally, Mcguire Capital Advisors Inc. purchased a new position in CVS Health during the 4th quarter valued at about $28,000. Institutional investors own 80.66% of the company’s stock.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,018,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the completion of the transaction, the director owned 5,195,261 shares of the company’s stock, valued at $487,419,387.02. This trade represents a 16.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

CVS Health Stock Down 3.3%

NYSE:CVS opened at $93.99 on Tuesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s 50-day moving average price is $102.46 and its 200-day moving average price is $88.41. The company has a market capitalization of $120.21 billion, a PE ratio of 24.87, a P/E/G ratio of 0.93 and a beta of 0.61. CVS Health Corporation has a 1-year low of $69.40 and a 1-year high of $110.68.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same quarter in the previous year, the firm posted $1.81 earnings per share. CVS Health’s quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, equities analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s dividend payout ratio is presently 70.37%.

Wall Street Analyst Weigh In

Several research firms have weighed in on CVS. Morgan Stanley increased their price objective on CVS Health from $106.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. TD Cowen boosted their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Cantor Fitzgerald upped their target price on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Argus raised their price target on CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Finally, Sanford C. Bernstein lifted their price target on shares of CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, May 12th. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.